2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
71
Neoplasms
28
Neoplasm Metastasis
15
Colorectal Neoplasms
9
Multiple Myeloma
6
Thyroid Neoplasms
5
Skin Neoplasms
5
Lymphoma, Non-Hodgkin
5
Carcinoma, Non-Small-Cell Lung
5
Thyroid Cancer, Papillary
4
Leukemia, Hairy Cell
4
Hematologic Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Breast Neoplasms
3
Wilms Tumor
2
Thyroid Carcinoma, Anaplastic
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoma
2
Interventions
Carboplatin
12
Paclitaxel
11
Gemcitabine
11
Capecitabine
7
Irinotecan
6
Fluorouracil
5
Cisplatin
5
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Bevacizumab
4
pembrolizumab
3
Filgrastim
3
Etoposide
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
etoposide phosphate
2
atezolizumab
2
Trastuzumab
2
Topotecan
2
Taxes
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Genetic Testing
2
FAPI-46
2
Docetaxel
2
CP protocol
2
Amifostine
2
Albumin-Bound Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
Vemurafenib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts